Clinical Trials Logo

Clinical Trial Summary

This study examines preoperative Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations.


Clinical Trial Description

Lung cancer remains the most common cause of cancer-related death in the world. Non-small-cell lung cancer (NSCLC) is the most common type, and it accounts for 85% of cases. Unfortunately, the majority of patients with NSCLC have metastatic disease at diagnosis. However, even patients with resectable disease have poor survival. The need to improve survival rates in these patients prompted research exploring the role of systemic therapy in operable NSCLC. In the 1990s, several clinical trials of preoperative chemotherapy (also known as induction chemotherapy) followed by surgery or radiation in patients with locally advanced NSCLC showed improvements in survival. Erlotinib is an orally administered tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR). The presence of somatic mutations in the kinase domain of EGFR strongly correlates with increased responsiveness to EGFR tyrosine kinase inhibitors. Recently three randomized phase III trials showed that first-line use of EGFR-TKIs in patients with EGFR mutant NSCLC significantly improved response rate and progression-free survival (PFS) compared to platinum-based chemotherapy. These findings prompted this phase II trial of preoperative Erlotinib in patients with operable stage II and IIIA NSCLC harboring EGFR mutations. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01470716
Study type Interventional
Source National Cancer Center, Korea
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 2012
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05157776 - A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations Phase 3
Completed NCT03736993 - Metabolomics Predict Therapy Response N/A
Recruiting NCT04205552 - Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients Phase 2
Withdrawn NCT03628144 - Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04865250 - Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC Phase 2